Clinical trials: ALL, Adult B Cell
ALL, Recurrent, Adult
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of…
- Trial name
- NCT05182385
- Testing
- Blinatumomab, Venetoclax
- Where
- 17 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Goethe University
T-ALL/Lymphoma
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.
- Trial name
- NCT06909474
- Testing
- Anti-CD5 CAR NK cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Healthy, Adult ALL
Motion Capture as a Tool for the Assessment of Laparoscopic Performance
The goal of this study is to 1) identify motion capture variables that can be used to differentiate surgical experience level and 2) evaluate if these variables can be used in a surgical education setting to improve resident…
- Trial name
- NCT04646304
- Testing
- Objective Feedback (Motion Capture)
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Adult ALL, Diabete Type 2
The Physical and Mental Health of People With Type II Diabetes Mellitus.
To analyze the effects of a Pilates exercise program on physical and mental health in people with type II diabetes mellitus.
- Trial name
- NCT05711602
- Testing
- Pilates
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- University of Jaén
Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
- Trial name
- NCT06581081
- Testing
- Senl_B19 autologous CAR-T (S1904) treatment
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT).
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
- Trial name
- NCT03751709
- Testing
- Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cedars-Sinai Medical Center
Adult ALL
Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM).
The investigators aim to evaluate English and Spanish versions of the "Attitudes toward genomics and precision medicine" instrument (AGPM).
- Trial name
- NCT06386861
- Testing
- Attitudes Toward Genomics and Precision Medicine (English), Attitudes Toward Genomics and Precision Medicine (Spanish)
- Where
- United States
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Boston College
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
This is a randomised, open-label, multicenter, phase III study for adult de novo Ph+ ALL patients based on the combination of Ponatinib with Blinatumomab.
- Conditions
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
- Trial name
- NCT04722848
- Testing
- Ponatinib + Blinatumomab, Chemotherapy + Imatinib
- Where
- 15 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
ALL, Adult
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
Blinatumomab is a new active bispecific monoclonal antibody for treatment of lymphoid malignancies, including ALL (acute Lymphoblastic Leukemia ) whose activity for remission induction needs to be explored in combination with…
- Trial name
- HOVON146ALL (NCT03541083)
- Testing
- Blinatumomab
- Where
- 18 sites in Belgium, Netherlands
- Volunteers
- 71 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
AML, Adult, Myelodysplastic Syndromes
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
- Conditions
- AML, Adult, Myelodysplastic Syndromes, ALL, Adult, CML, Refractory
- Trial name
- NCT03884829
- Testing
- CYC140
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Acute Lymphoblastic Leukemia, Adult, Ph+ ALL
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed
- Trial name
- Pona-CELL (NCT04554459)
- Testing
- Ponatinib 15 MG Oral Tablet
- Where
- 7 sites in Czechia
- Volunteers
- 4 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
ALL, Adult
Video-recOrded hospItal dischaRge (VOIR)
This study evaluates the suitability and acceptability of video-recorded discharge via the Patient Knows Best app. Through a randomized control trial, patients receive either standard discharge care or standard care supplemented…
- Trial name
- VOIR (NCT06512272)
- Testing
- Video recorded shared using a mobile application
- Volunteers
- 60 people
- Sponsor
- Anglia Ruskin University
ALL, Adult
Optimising Pharmacist-led Medication Reviews in Primary Care
An increasing number of people are diagnosed with long-term conditions and are prescribed medicines to manage these conditions. Medication reviews (MRs) are used to optimise medicines, improve health outcomes, and decrease…
- Trial name
- OPen (NCT05928104)
- Testing
- Medication review
- Where
- 3 sites in United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Adult ALL, Post-traumatic Stress Disorder
Effects of an EMDR Intervention on Traumatic and Obsessive Symptoms
The Eye Movement Desensitization and Reprocessing Protocol (EMDR) was first developed by Francine Shapiro in 1987 and can be adapted for online and in presence administration.
- Conditions
- Adult ALL, Post-traumatic Stress Disorder, Obsessive-Compulsive Disorder, Disgust
- Trial name
- MDL (NCT06110702)
- Testing
- EMDR
- Where
- Italy
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL
Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
This is a phase II interventional trial to evaluate the efficacy of blinatumomab followed by high-dose chemotherapy in the first-line treatment for Ph-negative acute lymphoblastic leukemia (ALL) in adults.
- Conditions
- Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed
- Trial name
- Blina-CELL (NCT04554485)
- Testing
- Blinatumomab
- Where
- 5 sites in Czechia
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
ALL, Adult, Philadelphia-Negative ALL
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as…
- Trial name
- BEAT-ALL-2024 (NCT06250959)
- Testing
- Blinatumomab Injection [Blincyto], Doxorubicin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Chen Suning
Glucose Metabolism Disorders, Dietary Habits
Dietary Impact on Continuous Glucose Monitoring
Cardiorespiratory fitness (CRF), also known as "exercise capacity", is the capacity of respiratory and circulatory systems to supply oxygen to skeletal muscle during exercise for the generation of energy.
- Conditions
- Glucose Metabolism Disorders, Dietary Habits, Pediatric ALL, Adult ALL
- Trial name
- NCT05845827
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
PreDiabetes, Overweight and Obesity
Zein Nanoparticles for Glycemic Control
The use of zein nanoparticles as vehicles for drug delivery is under study, but of the effects observed in empty nanoparticles, in laboratory animals, the reduction of glucose levels was something worth studying.
- Conditions
- PreDiabetes, Overweight and Obesity, Adult ALL
- Trial name
- GLUCOCAPS (NCT05560412)
- Testing
- Zein nanocapsules, control
- Where
- Spain
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Adult ALL, Healthy
Heel Wedges and Carbon Fiber Custom Dynamic Orthoses to Control Knee Biomechanics
The proposed study evaluates the effect of medial and lateral wedges and carbon fiber custom dynamic orthoses (CDOs) on lower limb forces and motion during walking.
- Trial name
- CDOKNEEpilot (NCT05209360)
- Testing
- Medial or Lateral Wedge, Carbon Fiber Custom Dynamic Orthosis
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Acute Lymphoblastic Leukemia, Philadelphia Chromosome
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
ABC study is a phase 2, single-arm, open-label study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in patients with newly diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL
- Trial name
- ABC (NCT06220487)
- Testing
- Prednisone, Olverembatinib, Blinatumomab, Chidamide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Nanfang Hospital, Southern Medical University